A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adults With Phenylketonuria
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs RTX-134 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Sponsors Rubius Therapeutics
- 14 Nov 2019 According to a Rubius Therapeutics media release, the company has successfully manufactured RTX-134 fro this trial.
- 14 Nov 2019 According to a Rubius Therapeutics media release, the company expect to report initial clinical results during the first quarter of 2020.
- 27 Sep 2019 Status changed from planning to recruiting.